Patent ID: 9745367
Date: 2017-08-29
CPC Classifications: A61K,A61P,C07K,G01N

Claim:
1. A method of selecting a genus of therapeutic antibodies, the method comprising: a) determining whether an antibody inhibits alternative pathway complement activation but not classical pathway complement activation or classical pathway initiated amplification of the alternative pathway by assaying the antibody for its ability to: b) determining whether the antibody inhibits C3b produced exclusively by the alternative pathway; c) and selecting an antibody which meets steps (a) and (b) above; wherein the selected antibodies bind to a component of Alternative Pathway C3 Convertase, which have the specific characteristic of selectively inhibiting C3a, C5a, C3b, C5b, and C5b-9 produced exclusively by the alternative pathway, without inhibiting any of the classical pathway's ability to produce C3a, C5a, C3b, C5b, and C5b-9 at levels sufficient to maintain normal host defense.